drugset / Trial / NCT01172379

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period Dyskinesias

NCT01172379

Phase 2 Completed 2 enrolled Eisai Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the safety, tolerability and efficacy of E2007 in Parkinson's Disease patients who have "wearing off" motor fluctuations and "on" period dyskenisias.

Timeline

Start
2004-05
Primary completion
2005-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Perampanel Small molecule 0.5 mg
Subject Perampanel Small molecule 1 mg
Subject Perampanel Small molecule 2 mg

Indications